CTC Capital Management’s ADMA Biologics ADMA Stock Holding History

CTC Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-17,600	Closed	-$32K	–	77
2022 Q1	$32K	Buy	+17,600	New	+$27.5K	0.09%	110

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

CTC Capital Management's ADMA Position: Q2 2022 in Review

CTC Capital Management sold out of ADMA Biologics (ADMA) in Q2 2022, closing a stake of 17,600 shares — an estimated $32K sold.

CTC Capital Management first reported a position in ADMA in Q1 2022 and held it in 1 quarter. The position peaked at $32K in Q1 2022. 113 funds tracked by Wall St. Rank hold ADMA as of Q2 2022.

CTC Capital Management reported no remaining ADMA Biologics position as of Q2 2022 after selling out during the quarter.
CTC Capital Management sold 17,600 ADMA Biologics shares in Q2 2022, an estimated $32K.
CTC Capital Management first reported a position in ADMA Biologics in Q1 2022 and held it in 1 quarter.
CTC Capital Management's ADMA Biologics position peaked at $32K in Q1 2022.
113 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2022.

Based on CTC Capital Management's 13F filing for Q2 2022, filed 5 Aug 2022.